Venetoclax in lymphoid malignancies: new insights, more to learn
- Author(s)
- Thijssen, R; Roberts, AW;
- Details
- Publication Year 2019-10-14,Volume 36,Issue #4,Page 341-343
- Journal Title
- Cancer Cell
- Publication Type
- Journal Article
- Abstract
- In this issue of Cancer Cell, Guieza et al. describe that overexpression of the pro-survival protein MCL1 and cellular energy metabolic reprogramming can contribute to resistance to the BCL2 inhibitor venetoclax in patients with chronic lymphocytic leukemia. This adds a new dimension to understanding of secondary clinical resistance to venetoclax.
- Publisher
- Cell Press
- Research Division(s)
- Blood Cells And Blood Cancer
- PubMed ID
- 31614111
- Publisher's Version
- https://doi.org/10.1016/j.ccell.2019.09.008
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2019-10-28 12:05:04
Last Modified: 2019-10-30 09:42:58